Evidence map›Paper›PMID 39802100›Full record

ArticleBiologics : targets & therapy2025

First Indonesian Nasopharyngeal Cancer Whole Epigenome Sequencing Identify Tumour Suppressor CpG Methylation.

Handoko, Marlinda Adham, Lisnawati Rachmadi, Demak Lumban Tobing, Asmarinah, Fadilah, Wei Dai, Anne Wing Mui Lee, Soehartati A Gondhowiardjo

Abstract read
In one paragraph

Article in Biologics : targets & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

HandokoDoctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID 0000-0002-2834-9090
Marlinda AdhamFaculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Lisnawati RachmadiFaculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID 0000-0002-5307-3671
Demak Lumban TobingDepartment of Clinical Pathology, Dharmais Cancer Hospital, Jakarta, Indonesia.
AsmarinahMedical Biology Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.ORCID 0000-0001-5204-4054
FadilahDepartment of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia-Bioinformatics Core Facilities, Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Wei DaiDepartment of Clinical Oncology, University of Hong Kong, Pokfulam, Hong Kong (SAR), People's Republic of China.
Anne Wing Mui LeeClinical Oncology Center, University of Hong Kong - Shenzhen Hospital, Shenzhen, People's Republic of China.
Soehartati A GondhowiardjoFaculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID 0000-0002-9446-4361

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Nasopharyngeal cancer (NPC) is a multifaceted disease characterized by genetic and epigenetic modifications. While Epstein-Barr virus (EBV) infection is a known risk factor, recent studies highlight the significant role of DNA methylation in NPC pathogenesis. Aberrant methylation, particularly at CpG sites, can silence tumour suppressor genes, promoting uncontrolled cell growth. This study aims to analyse the methylation patterns in Indonesian NPC patients through whole-epigenome sequencing. Methods: Seven clinical nasopharyngeal cancer samples were collected and confirmed histopathologically. DNA was extracted, sequenced using Oxford Nanopore technology, and aligned to the GRCh38 human reference genome. Methylation analysis was performed using modkit and statistical analysis with R software. Enriched pathways and processes were identified using ClusterProfiler in R, and gene overlap analysis was conducted. Results: The analysis identified both globally hypermethylated and hypomethylated NPC samples. Key tumour suppressor genes, such as Discussion: This study provides comprehensive insights into the epigenetic landscape of NPC, underscoring the role of CpG methylation in tumour suppressor gene silencing. These findings pave the way for targeted therapies and highlight the need for region-specific approaches in NPC management.

Indexed as

epigenomeEpstein–Barr virusmethylationnasopharyngeal cancerwhole-genome sequencing

Identifiers

PMID39802100
PMCPMC11721153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.